Table 2.

Composite Primary End Point and Components of the Primary End Point.

4-Year Study Period (Including Periprocedural Period*)
	No. of Patients (%±SE)
	CAS (N = 1262)	CEA (N = 1240)	Absolute Treatment Effect of CAS vs. CEA (95% CI) Percentage Points	P†
Stroke
Any stroke	105 (10.2 ± 1.1)	75 (7.9 ± 1.0)	2.3 (−0.6 to 5.2)	0.03
Major ipsilateral	16 (1.4 ± 0.3)	6 (0.5 ± 0.2)	0.8 (0.1 to 1.6)	0.05
Minor ipsilateral	52 (4.5 ± 0.6)	36 (3.5 ± 0.6)	1.0 (−0.7 to 2.7)	0.10
Primary end point (any periprocedural stroke, myocardial infarction, or death or post procedural ipsilateral stroke)	85 (7.2 ± 0.8)	76 (6.8 ± 0.8)	0.4 (−1.7 to 2.6)	0.51

^*For patients who received the assigned procedure within 30 days after randomization, the periprocedural period was defined as the 30-day period after the procedure. For patients who did not receive the assigned procedure within 30 days after randomization, the periprocedural period was defined as the 36-day period after randomization.

^†P values were calculated based upon significance of the hazard ratios.⁷